Discuss Thymosin Alpha-1 on glp1chat
Join the forum to discuss research with other members.
At a glance
Thymosin alpha-1 acts on parts of the immune system that coordinate responses to infection and inflammation. Studies in different conditions measure how immune-cell signals and clinical outcomes change; the effect depends on the setting.
Immune cells have to recognize a threat, coordinate with one another and then quiet down when the job is done. Thymosin alpha-1 is studied for changes in that coordination, including signals involving T cells. Studies across infections and other conditions ask different questions, so there is no single universal 'immune boost' outcome. The effect needs to be read in the setting actually tested.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited literature spans different conditions and study designs. Outcomes and safety need to be assessed separately for each setting.[1][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Thymosin Alpha-1.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 300 mcg (0.3 mg) | 18 units (0.18 mL) |
| Weeks 2–8 | 500 mcg (0.5 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This 8‑week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges[4]. Treatment durations of 8–16 weeks are commonly reported in literature.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support immune modulation and enhance host defense mechanisms[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 300–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 7 days.
Suggested daily titration approach.
- Start: 300 mcg daily for Week 1 to assess tolerance.
- Target: 500 mcg daily from Week 2 onward.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term; minimize moisture exposure[4].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days when using bacteriostatic water; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Thymosin Alpha-1, 5 mg each):
- 8 weeks ≈ 6 vials
- 12 weeks ≈ 9 vials
- 16 weeks ≈ 12 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
- 16 weeks (12 vials): 36 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 04
- 05
Research publication
Clinical Immunology — Mechanisms of thymosin alpha-1 immunomodulation: T-cell maturation and cytokine production (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
Hospital Pharmacy — Jordan et al. (2021): Small-volume injection accuracy; recommends ≥20% syringe capacity for precision (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration required) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection: site selection, rotation, and technique (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 09
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, site rotation, and administration (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑